Puma Biotechnology, Inc. (PBYI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 225 | 253 | 228 | 236 | 230 | 228 | 231 | 226 |
| Operating profit | $m | 37 | 30 | ||||||
| Net profit | $m | -60 | -29 | 0 | 22 | 30 | 31 | 27 | 19 |
| EPS reported | $ | 0.61 | 0.52 | ||||||
| Operating cashflow per share | $ | 0.84 | 0.81 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.83 | 0.81 | ||||||
| Free cash flow | $m | 42 | 41 | ||||||
| Net debt | $m | -75 | -94 | ||||||
| Book value equity | $m | 130 | 139 | ||||||
| Book value per share | $ | 2.57 | 2.63 | ||||||
| Number of shares | m | 50.65 | 52.6 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 9.75 | 18.93 | ||||||
| P/B LTM | x | 2.28 | 2.15 | ||||||
| P/S LTM | x | 1.30 | 1.29 | ||||||
| P/FCF LTM | x | 7.13 | 7.23 | ||||||
| EV/EBITDA LTM | x | 5.56 | 6.22 | ||||||
| EV/Sales LTM | x | 1.30 | 1.81 | ||||||
| Earnings Yield LTM | % | +10.26% | +5.28% | ||||||
| FCF Yield | % | +14.02% | +13.83% | ||||||
| Quality | |||||||||
| ROE | % | +23.87% | +20.85% | ||||||
| ROIC | % | +20.41% | +18.20% | ||||||
| Operating margin | % | +16.33% | +13.16% | ||||||
| Gross margin | % | +74.53% | +74.83% | ||||||
| FCF/Sales | % | +18.27% | +17.80% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -1.61% | -16.13% | ||||||
| Sales Growth YoY | % | -0.91% | +0.34% | ||||||
| Net Income Growth YoY | % | +2.75% | -11.76% | ||||||
| FCF Growth | % | +7.38% | +5.91% | ||||||
| Operating Profit Growth | % | +20.45% | -1.71% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 1.46 | 8.54 | ||||||
| Net Debt/EBITDA | x | -0.02 | -0.67 | ||||||
| EBIT/Net interest | x | 5.63 | 8.65 | ||||||
| Net debt/market cap | % | +7.57% | 0.00% | ||||||
| Net debt/Equity | x | -0.58 | -0.68 | ||||||
| Gross debt/equity | x | 0.22 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free